Nationally Ranked
MUSC Hollings Cancer Center is ranked as the No. 1 hospital in South Carolina for cancer care in the latest U.S. News & World Report rankings. In addition, Hollings is also ranked as high performing for colon cancer surgery, gynecological cancer surgery, leukemia, lymphoma and myeloma, lung cancer surgery and prostate cancer surgery. MUSC Shawn Jenkins Children’s Hospital is #33 on the list of best children's hospitals for cancer.
Magnet Recognition
MUSC has been awarded with Magnet Recognition®, an acknowledgment of quality patient care, nursing excellence, and innovations in professional nursing practice.
Commission on Cancer
In 2026, the cancer programs in Charleston, Orangeburg and Florence were awarded initial accreditation as an Integrated Network Cancer Program (INCP) by the American College of Surgeons Commission on Cancer (CoC). This achievement reflects MUSC’s commitment to delivering high-quality cancer care across the continuum and throughout South Carolina.
CoC accreditation is awarded to institutions that demonstrate compliance with rigorous standards designed to ensure excellence in cancer care. Accredited programs undergo comprehensive evaluations of performance and adherence to CoC standards, with site visits required every three years to maintain accreditation. These standards provide the framework for ensuring patients have access to a full range of diagnostic, treatment, supportive and community-based services, either on-site or through referral partnerships. These sites apply a multidisciplinary approach and treat cancer as a complex group of diseases that requires consultation among surgeons, medical and radiation oncologists, diagnostic radiologists, pathologists, and other healthcare professionals who specialize in oncology. Cancer patients benefit from having access to clinical trials, screening and prevention events, palliative care, genetic counseling, rehabilitation, oncology nutrition and survivorship services.
With this accreditation, MUSC Florence Medical Center joins MUSC Charleston Medical Center (accredited since 1936) and MUSC Orangeburg Medical Center (accredited since 2020) as a CoC-accredited site. In addition to maintaining individual site accreditation, all three programs must meet and sustain additional integrated network standards that link and strengthen the cancer programs across the health system.
National Accreditation for Radiation Oncology
The Radiation Oncology team is accredited by the American College of Radiology.
National Accreditation Program for Rectal Cancer
The Rectal Cancer program is accredited by the National Accreditation Program for Rectal Cancer and is one of a select group of cancer centers across the country to achieve this recognition.
National Accreditation Program for Breast Centers
Our Breast Care program is accredited by the National Accreditation Program for Breast Centers.
Comprehensive Breast Imaging Center
MUSC Hollings Cancer Center in Charleston and MUSC Health Florence Medical Center have both been awarded the Comprehensive Breast Imaging Center designation by the American College of Radiology. This designation signifies that these locations have met the rigorous standards of accreditation within four types of breast imaging:
- Mammography.
- Stereotactic breast biopsy.
- Breast ultrasound.
- MRI in the breast module.
Foundation for the Accreditation of Cellular Therapy
The Blood & Marrow Transplant program at Hollings has been accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) since 2003.
National Pancreas Foundation Center of Excellence
Hollings has been recognized as a center of excellence for pancreatic cancer care by the National Pancreas Foundation.
VHL Alliance-designated Clinical Affiliate
MUSC has earned Clinical Affiliate status with the VHL Alliance, a designation that indicates a center that provides holistic, comprehensive care for people with von Hippel-Lindau disease.
Elite GammaTile Center
MUSC Hollings Cancer Center is the first in South Carolina to achieve Elite GammaTile Center status by completing 10 GammaTile Therapy implant procedures. GammaTile Therapy is a novel Surgically Targeted Radiation Therapy (STaRT) for operable brain tumors. Implanted in the last five minutes of brain tumor removal surgery, each bioresorbable, 3D-collagen GammaTile is embedded with radiation sources. GammaTile Therapy delivers a sustained, controlled, therapeutic radiation dose, targeting tumor cells while sparing healthy tissue.
In the past 50 years, only seven drugs or devices have been FDA-approved or -cleared to treat brain tumors. GammaTile Therapy was FDA-cleared in 2018 for recurrent brain tumors, including recurrent high-grade gliomas, glioblastomas, meningiomas and brain metastases. In 2020, the FDA expanded that indication to include newly diagnosed malignant brain tumors.
